Trend of clinical trials of new drugs for rare diseases in China in recent 10 years

Author:

Peng Ai1,Fan Xue2,Zou Linling1,Chen Huan1,Xiang Jin1ORCID

Affiliation:

1. Clinical Trial Center, West China Hospital, Sichuan University

2. Key laboratory of drug Targeting and Drug Delivery systems, West China School of Pharmacy, Sichuan University, China

Abstract

Abstract Background: Rare disease is a general term for a disease that affects a small number of people but be recognized as a global public health priority. Governments worldwide are paying more and more attention to the academical research and drug investment of rare diseases. The conduct of rare disease clinical trials is still difficult, despite the promotion of government policies and the awakening of social consciousness. In this article, we outlined the characteristics and obstacles of clinical trials of rare diseases in China and expected to provide reference for subsequent clinical trials in this field. Results: In the recent years, China has made some progress in clinical trials of rare diseases in the past 10 years. There are a total of 481 clinical trials on rare diseases, covering more than 10 rare diseases with high incidence. Clinical trial applications on rare diseases for a total of 481 were submitted and with an average annual growth rate of 28.2% from 2013 to 2022. The number of clinical trial application for rare diseases in 2016 dramatically increased by 80% compared to 2015 due to the policy document issued by China for clinical research in rare diseases in 2015. Besides, about 70% of applications registering for clinical trials could recruit subjects as expected. Despite this, the number of clinical trials of rare diseases in China is smaller than that of the United States, Europe and Japan, and the types of infant drugs are limited to biological products and chemical drugs lacking other new treatments. Conclusions: Efforts have been made in recent years to develop clinical research on rare diseases in China. The number of clinical trials for rare diseases in China is growing steadily every year, which is inseparable from the support of the country, society and rare disease patients. Still, there is a large gap between China and other developed countries in this field and this merit further investigation.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3